Saxenda (liraglutide 3 mg) / Novo Nordisk - LARVOL DELTA

Evaluating GLP-1 receptor agonists in treating pediatric obesity within the context of social determinants of health: A systematic review and meta-analysis (PAS 2025) - "Although Wegovy (semaglutide) and Saxenda (liraglutide) have been FDA-approved, public insurance programs like Medicaid do not cover their costs. Eight RCTs were included in this review (N = 711; ages 6-19). The combined Hedges’ g values were: -0.32 (95% confidence interval: [−0.49, −0.15]) for BMI, -0.34 (−0.51, −0.18) for BMI-SDS, and -0.35 (−0.50, −0.19) for weight change, indicating small to moderate reductions in these measures for treatment groups. Conclusion(s) : This meta-analysis highlights a significant treatment effect of GLP-1RAs on pediatric obesity."

Retrospective data • Review • Diabetes • Genetic Disorders • Obesity • Pediatrics

Real-world data on the effectiveness of liraglutide (Saxenda) and naltrexone/bupropion (Mysimba) on weight loss outcomes up to 2 years in clinical practice (ECO 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence

A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland. (PubMed, Value Health) - "The MAP facilitates access for a subpopulation in whom liraglutide is effective and also expected to be most cost-effective, according to HTA."

Journal • Observational data • Retrospective data

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

Institute for Clinical and Economic Review Releases Obesity Medications White Paper Examining Strategies to Ensure Affordable Access (Institute for Clinical and Economic Review) - "The Institute for Clinical and Economic Review (ICER), in collaboration with researchers from Brown University, has published a new white paper today that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications. The paper, entitled, “Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions,” seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications."

HEOR • Obesity

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. (PubMed, Cureus) - "This literature review evaluates and compares the effectiveness of four pharmacological agents semaglutide, liraglutide, orlistat, phentermine, and emerging agents like setmelanotide, amycretin, retatrutide, cagrilintide, and cotadutide in managing weight loss among obese. A detailed analysis was conducted on their mechanisms of action, dosing regimens, efficacy in weight loss, safety profiles, and their impact on obesity-related comorbidities. Although all agents presented distinct benefits, side effects such as gastrointestinal discomfort with orlistat and GLP-1 receptor agonists, and potential dependency with phentermine, necessitate tailored treatment approaches. This review highlights the importance of integrating pharmacotherapy with lifestyle interventions to achieve sustainable weight management and identifies areas for future research to optimize therapeutic outcomes for individuals with obesity."

HEOR • Journal • Review • Cardiovascular • Gastrointestinal Disorder • Genetic Disorders • Obesity

“Extension of indication to include the use of SAXENDA for weight management in children from the age of 6 years to less than 12 years based on results from study NN8022- 4392… as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted” (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 10 – 13 Feb 2025

PRAC • Obesity

Effect of Meal Replacement Compared with Liraglutide 3.0 mg on Weight Loss and Hepatic Steatosis before Bariatric Surgery—A Randomised Study (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Bariatric surgery • Clinical • Surgery • Metabolic Disorders

Saxenda: Newly added patents in Orange Book (Orange Book) - Expiry on Oct 20, 2025, Jan 20, 2026, Apr 20, 2026, Jul 17, 2026, Jul 20, 2026, Jul 26, 2026, Aug 3, 2026, Jan 17, 2027, Feb 3, 2027, Feb 27, 2027, Aug 27, 2027, Sep 27, 2027, Mar 27, 2028, Feb 1, 2032, Aug 1, 2032

Patent • Metabolic Disorders • Obesity

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. (clinicaltrials.gov) - P=N/A | N=288 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Analysis of Employer Coverage of Weight Loss Therapies (ISPOR 2025) - "71% of workers have access to Wegovy through their employer, and 54% have access to Saxenda. This analysis will help policymakers gain a better understanding of employee coverage decisions so they can develop optimal policies that balance the financial costs against the health and economic benefits of weight loss therapies. Further research is needed on the drivers behind the correlations presented in this analysis. The findings will also help manufacturers conduct out-reach to employers, and appeal to their unique needs, such as the ability to compete for talent and prevention of morbidities that can hinder the ability to work."

Genetic Disorders • Obesity

Saxenda: Underlying Mechanisms and Clinical Outcomes (clinicaltrials.gov) - P4 | N=28 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) AND OBESITY, THE USE OF LIRAGLUTIDE, DECREASES VISCERAL ABDOMINAL FAT, AND INCREASES OVULATION RESUMPTION (ATTD 2025) - "Background and Aims: Anovulatory PCOS in obese women is usually managed with a lifestyle program + metformin, but is often unsatisfactory. In anovulatory women with PCOS and obesity, liraglutide 3.0 mg/die was effective in decreasing VAT and increasing ORR. An early and consistent VAT loss is related to ovulation resumption. Future studies should address the mechanisms behind these changes and evaluate interventions aimed at VAT reduction to facilitate ovulation resumption."

Clinical • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (PubMed, Expert Opin Investig Drugs) - "Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes. This review describes results obtained with GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon co-agonists, and the triple agonist retatrutide (GIP/GLP-1/glucagon), which have shown beneficial effect both on body weight and steatotic liver disease. A combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration is currently in phase III development, and so is oral semaglutide and several non-peptide small molecule GLP-1 agonists for oral administration...The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future...."

Journal • P2 data • Review • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone (clinicaltrials.gov) - P4 | N=72 | Not yet recruiting | Sponsor: Medical University of Vienna

New P4 trial • Genetic Disorders • Obesity

Novo shares rise as HIMS halt sales of some obesity drugs (Yahoo Finance) - "Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in Novo’s weight-loss drugs...According to Bank of America analysts, the decision to halt commercial semaglutide doses is a positive development for Novo, which has faced concerns over the impact of compounded versions on its GLP-1 drug franchise...'While Hims&Hers will stop offering commercial semaglutide doses after Q1 2025.'....Instead, its weight-loss program will now focus on oral-based solutions and liraglutide (Saxenda), which is also a Novo product."

Commercial • Obesity

Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: University of California, Los Angeles | N=40 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Congestive Heart Failure • Genetic Disorders • Obesity • Pulmonary Disease

Tirzepatide (Zepbound) for obstructive sleep apnea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options. (PubMed, Endocrinol Metab Clin North Am) - "The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication."

Journal • Review • Genetic Disorders • Obesity

Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial. (PubMed, Osteoarthr Cartil Open) - P4 | "This indicates a complex pattern of proinflammatory cytokine-release during hypocaloric diet interventions. Clinicaltrials.gov: NCT02905864."

Clinical • Journal • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology • LCN2

Longitudinal Analysis of Obesity Drug Use and Public Awareness. (PubMed, JAMA Netw Open) - "Phentermine, semaglutide (Wegovy; Novo Nordisk), liraglutide (Saxenda; Novo Nordisk), and tirzepatide (Zepbound; Eli Lilly) were most prescribed. This repeated cross-sectional study shows the dynamic growth and evolving share of new obesity medications since 2017 and a significant shift toward semaglutide and tirzepatide prescribing. The joint surge in prescriptions and online searches and their close correlation highlight the real-time associations between public awareness and prescription trends."

Journal • Genetic Disorders • Obesity

Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis. (PubMed, Pharmacoecon Open) - "Semaglutide 2.4 mg is likely to be a short-term, cost-effective treatment option for adults who are overweight or have obesity without diabetes in Greece."

Clinical • HEOR • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. (PubMed, Geroscience) - "Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. In conclusion, GLP1R expression levels serve as an important biomarker with potential prognostic significance across multiple cancers, demonstrating both protective and adverse associations depending on the tumor type. These findings highlight the complex role of GLP-1R agonists in cancer risk and survival, suggesting that the therapeutic use of these agents should be carefully tailored to the individual patient's cancer risk profile."

Journal • Bladder Cancer • Breast Cancer • Cervical Cancer • Cervical Squamous Cell Carcinoma • Clear Cell Carcinoma • Clear Cell Renal Cell Carcinoma • Colon Cancer • Colorectal Cancer • Diabetes • Endocrine Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Genetic Disorders • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Obesity • Oncology • Ovarian Cancer • Pancreatic Cancer • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus • Uterine Cancer

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity • Oncology

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (clinicaltrials.gov) - P4 | N=500 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity